Advisory Board

CV

Philipp von Lattorff (Chairman Advisory Board ViraTherapeutics) started his career at IBM Austria in 1991. Two years later, he joined Boehringer Ingelheim, Vienna, in the area management for Eastern Europe. Other significant stages along his way were management functions in the Baltic region, in Hungary and Italy as well as Regional Business Management Positions for Europe and as CEO for the Central and Eastern European region for CSC pharmaceuticals. In 2011, he joined Boehringer Ingelheim as Head of Emerging Markets before taking over his current role as Country Managing Director of the Boehringer Ingelheim Regional Center Vienna in 2013 where he is responsible for the company’s pharmaceutical business in more than 30 countries in Central and Eastern Europe, Central Asia and Israel.

CV

Personal Details

Name:	Derek O’Leary
Date of birth:	31.01.1970
Place of birth:	Enniscorthy, Co. Wexford, Ireland
Nationality:	Irish
Professional Experience
06/2019 – now	Head of Finance & Administration RCV
02/2013 – 05/2019	CFO/Head of Finance Division Boehringer Ingelheim Japan Inc.
10/2007 – 01/2013	Head of Finance & Administration BI Espana
11/2002 - 09/2007	Finance Director BI Ilac Ticaret (BI Turkey)
04/2001 – 10/2002	Country Controller, Corp. Dept. Subsidiaries Controlling, BI GmbH
07/1997 – 03/2001	Regional Controller, BI Pharma Orient, Egypt
10/1994 – 06/2007	Project Controller, Methods & Procedures, Corp. Division Controlling, BI GmbH
01/1992 – 09/1994	Financial Analyst, Alfa Metalcraft Corporation, Bingen, Germany
07/1991 – 12/1991	Credit Controller, Triton Finance, Rank Xerox Financial Services, Slough, UK
Education:
1988 - 1991	BA in Accounting & Finance, Dublin City University, Ireland
1984 – 1988	FCJ Bunclody, Co. Wexford, Ireland completion of leaving certificate (abitur equivalent)

Language Skills

English – native
Irish – native
German – fluent
Spanish – fluent
French – conversational
Turkish - conversational
Japanese – N3 proficient, intermediate
Italian - basic

Additional Skills:

Treasurer of Ireland/Japan Chamber of Commerce, Experience in organizing charitable events

Additional courses:

Global Strategic Leadership Program, Situational Leadership, Management Centre Europe, Center for Creative Leadership, plus various others

Interests:

Foreign languages and culture, travel, listening to music & podcasts, sports (gym, football, tennis), spending time with family

CV

Jonathon Sedgwick, B.Sc. (Hons) Ph.D. born Perth Australia, is an Immunologist, educated at the University of Western Australia with post-doctoral education at the University of Oxford. His subsequent career included positions in academic research in Germany and Australia, Group Director Immunology at the biotech Company DNAX, in Palo Alto, California and 11 years with Eli Lilly and Company where he held a number of roles including Chief Scientific Officer, Cancer Inflammation Research; Managing Director and Chief Scientific Officer of Lilly’s Singapore Research Center, and Chief Scientific Officer, Autoimmunity Discovery. In November 2015, Dr. Sedgwick joined Boehringer Ingelheim, based at the Ridgefield CT USA research site. He holds the position of Vice President and Global Head Cancer Immunology and Immune Modulation Research. He has responsibility across four global sites for the development of the Immuno-oncology discovery and early clinical portfolio, and for immune-modulation research. Amongst his key contributions to the immunology field was the discovery with colleagues at DNAX of the dominant biological role of the interleukin-23 cytokine in autoimmune inflammation, and through this identifying the IL-17-producing T cell subset, Th17. These discoveries have underpinned a number of breakthrough medicines in the autoimmunity field. Dr. Sedgwick has authored or co-authored 120 peer-reviewed, review articles and book chapters.

CV

Besides serving as a member of the Supervisory Board of ViraTherapeutics, Dr. Ralf Schumacher is currently the Head of Development Biologicals in the Development Unit within Boehringer Ingelheim. In this capacity, he is accountable for all non-clinical development activities which are required to bring a biological clinical candidates into clinics and subsequently through clinical development up to launch. Corresponding disciplines comprise all CMC functions (from cell line development, USP, DSP, Analytics, Formulation, Primary Packaging up to Combination Product development), DMPK (bioanalytical method development, PK & ADA studies in animals and humans), and non-clinical drug safety. Soon, a unit for clinical trial supplies will be added. The units are located in Germany and the US. Boehringer Ingelheim is committed to innovation and strives for development of first-in-class Biologicals with breakthrough potential. The Biologicals' portfolio includes monoclonal antibodies, engineered multi-functional NBEs, and new (ATMP) modalities.